Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. Wise on the Development of Precision Medicine in Prostate Cancer

January 30th 2018

David R. Wise, MD, PhD, assistant professor, Department of Medicine, assistant professor, Department of Urology, NYU Langone’s Perlmutter Cancer Center, discusses ongoing trials at NYU that are investigating precision oncology hypotheses.

Expert Shares Insight on Immunotherapy, Emerging Strategies in Prostate Cancer

January 30th 2018

David R. Wise, MD, PhD, discusses the promise for immunotherapy and other emerging approaches in the field of prostate cancer.

Screening Continues to Evolve in Prostate Cancer

January 30th 2018

Marc A. Bjurlin, DO, discusses ongoing efforts to optimize prostate cancer screening.

Dr. Taneja Discusses Imaging Techniques Used to Detect Metastatic Prostate Cancer

January 27th 2018

Samir Taneja, MD, James M. Neissa and Janet Riha Neissa professor of urologic oncology, vice chair, Department of Urology, professor, Department of Radiology, co-director, Smilow Comprehensive Prostate Cancer Center, director, Urologic Oncology, Genito-Urologic program leader, NYU Langone’s Perlmutter Cancer Center, discusses a number of emerging imaging techniques used to stage prostate cancer.

Differentiating Molecular Risk Assessments of Prostate Cancer

January 26th 2018

Marc A. Bjurlin, DO, clinical assistant professor, Department of Urology, NYU Langone Medical Center, discusses differentiating molecular risk assessments for patients with prostate cancer.

10-Year PROTECT Data Underscore Significance of Precision Medicine in Prostate Cancer

January 22nd 2018

Malcolm Mason, MD, discusses the significance of the 10-year follow-up of the PROTECT study for patients with prostate cancer and what it means for the field going forward.

CTCs Better Overall Survival Predictors Than PSA in mCRPC

January 21st 2018

An analysis of results from 5 clinical trials showed that circulating tumor cell (CTC) conversion and CTC value ≥ 1 at baseline were superior predictors of overall survival than PSA in men with metastatic castration-resistant prostate cancer.

Dr. Morgan on Enrolling Patients With Prostate Cancer onto Clinical Trials

January 20th 2018

Alicia Morgan, MD, Mather Hospital, discusses enrolling patients with prostate cancer onto clinical trials investigating PARP inhibitors.

Dr. Agarwal on Treatment for Newly Diagnosed Prostate Cancer

January 20th 2018

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses treatment options for patients with newly diagnosed prostate cancer.

Genetic Model Predicts Age of Onset for Aggressive Prostate Cancer

January 20th 2018

By combining data from genome-wide association studies with epidemiological surveys, investigators say they have developed a genetic tool that can predict age of onset for aggressive prostate cancer.

Dr. Sweeney on Chemotherapy in Prostate Cancer

January 19th 2018

Christopher Sweeney, MBBS, medical oncologist, Dana-Farber Cancer Institute, discusses when to give docetaxel as a treatment option for patients with prostate cancer.

Dr. Mason on the Significant Results from the PROTECT Study in Prostate Cancer

January 18th 2018

Malcom Mason, MD, Cancer Research Wales Professor of Clinical Oncology at Cardiff University, discusses the significant results of the PROTECT study for patients with prostate cancer.

Abiraterone Associated With Improved PROs in Metastatic Prostate Cancer

January 17th 2018

Men with newly diagnosed mCRPC in the global LATITUDE trial reported clinical improvements in pain progression, prostate cancer symptoms, fatigue, functional decline, and overallHR-QOL following treatment with abiraterone acetate plus prednisone.

Dr. Morgan on the Role of PARP Inhibitors in Prostate Cancer

January 17th 2018

Alicia Morgan, MD, Mather Hospital, discusses the role of PARP inhibitors for patients with prostate cancer.

Dr. Oh Discusses Immunotherapy in Prostate Cancer

January 13th 2018

William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of medicine and urology, Mount Sinai Hospital, discusses the role of immunotherapy for patients with prostate cancer.

Experts Discuss Optimal Timing of New Prostate Cancer Therapies

January 13th 2018

Layering of therapies and advances in next-generation imaging and sequencing are key reasons that outcomes are improving in advanced prostate cancer.

Dr. Agarwal on the Advantages of Docetaxel in Prostate Cancer

January 12th 2018

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses the advantages and disadvantages of choosing docetaxel as a therapy for patients with mCRPC.

Metastasis-Directed Therapy Shows Promise in Oligorecurrent Prostate Cancer

January 12th 2018

For patients with oligorecurrent prostate cancer, androgen deprivation therapy–free survival was superior for those assigned to metastasis-directed therapy versus surveillance.

Bipolar Androgen Therapy Effective After Enzalutamide in mCRPC

January 11th 2018

One-third of asymptomatic men with metastatic castration-resistant prostate cancer who progressed on enzalutamide (Xtandi) achieved a 50% decline in PSA concentration from baseline (PSA50) following bipolar androgen therapy.

Dr. Sweeney Discusses Tailoring Treatment in Prostate Cancer

January 11th 2018

Christopher Sweeney, MBBS, medical oncologist, Dana-Farber Cancer Institute, discusses tailoring treatment to individual patients with prostate cancer.